Background Despite advances in the treatment of Hodgkin lymphoma with the introduction
of PET-adapted regimens, practical challenges prevent more widespread use of these
approaches. The ECHELON-1 study assessed the safety and efficacy of front-line A+ AVD
(brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD
(doxorubicin, bleomycin, vinblastine, and dacarbazine) in patients with stage III or IV
classical Hodgkin lymphoma. The primary analysis showed improved modified progression …

The phase 3 ECHELON-1 study demonstrated that brentuximab vedotin (A) with
doxorubicin, vinblastine, and dacarbazine (AVD; A+ AVD) exhibited superior modified
progression-free survival (PFS) vs doxorubicin, bleomycin, vinblastine, and dacarbazine
(ABVD) for frontline treatment of patients with stage III/IV classical Hodgkin lymphoma (cHL).
Maturing positron emission tomography (PET)-adapted trial data highlight potential
limitations of PET-adapted approaches, including toxicities with dose intensification and …